Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer

Inclusion Criteria: * Newly diagnosed Stage IIIB or IV non-resectable NSCLC. Recurrent disease after resection for earlier stage disease is acceptable as long as patients are at least 6 months from surgery. * Treatment plan includes a platinum-based doublet chemotherapy. * ECOG 0, 1 or 2. * Self-reported loss of body weight or anorexia. * Serum C-reactive protein ≥5 mg/L. * Life expectancy of at least 6 months. * Adequate bone marrow, liver and renal function. * Normal serum potassium. * Ability to comply with the study requirements and give written informed consent. Exclusion Criteria: * Known physical or functional obstruction of the gastrointestinal tract, malabsorption, intractable vomiting, uncontrollable diarrhea, concurrently receiving tube feeding or parenteral nutrition, or unable to swallow investigational drug product. * Concomitant therapy with an appetite stimulant. * History of poorly controlled hypertension or congestive heart failure. * Any implanted devices that could interfere with DXA scanning. * Prolongation of QT interval. * History of additional risk factors for torsades de pointe. * Concomitant therapy with beta-adrenergic receptor antagonists (beta-blockers) or ergot derivatives. * Females who are breast feeding, pregnant or of child-bearing potential who are not using adequate birth control. * Any second malignancy which might confound the interpretation of safety or efficacy assessments. * Any condition which increases the patient's risk for participating in the study.